What is Promacta (eltrombopag)?
Promacta is a prescription medicine containing eltrombopag, a thrombopoietin receptor agonist. It is used to treat low platelet counts (thrombocytopenia) in certain conditions where the body is not making enough platelets or where platelets are being destroyed or used up too quickly.
What is Promacta used for?
Promacta is prescribed for thrombocytopenia in specific disease settings (for example, immune thrombocytopenia and some liver-disease–related causes of low platelets). Coverage and exact indications depend on the country’s labeling and prescribing guidelines.
How does Promacta work?
Eltrombopag works by activating the thrombopoietin receptor in the body. This signaling increases platelet production, which can raise platelet counts and reduce the risk of bleeding associated with low platelets.
How are Promacta tablets typically taken?
Dosing depends on the underlying condition, baseline platelet count, and how platelets respond over time. In many regimens, doctors start with a dose and then adjust based on platelet response to reduce the risk of excessively high platelet counts.
What side effects do patients ask about?
Common concerns with eltrombopag/Promacta often include effects related to blood counts and liver function monitoring, since platelet levels can rise and eltrombopag has liver-related safety considerations that require lab follow-up during treatment.
What monitoring is required while taking Promacta?
Patients typically need periodic blood tests to monitor platelet counts and other safety labs, with dose adjustments based on results. If Promacta is used in liver-related indications, liver tests are especially important during therapy.
Who makes Promacta, and is there a generic or biosimilar?
If you are trying to find whether Promacta has generics or what competition looks like, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Promacta and can help you check the current status of related patents: DrugPatentWatch.com - Promacta (eltrombopag).
Key safety questions patients should raise with their clinician
If you’re considering or already taking Promacta, key questions to discuss with a clinician include:
- Your target platelet range and when dosing will change based on lab results
- Liver-function monitoring schedule
- What to do if platelet counts rise too much
- Any drug interactions that could affect eltrombopag levels or safety
If you share what you’re looking for specifically (uses/indications, dosing, side effects, interactions, or patent/generic status by country), I can narrow the answer to that exact Promacta question.
Sources:
1. DrugPatentWatch.com - Promacta (eltrombopag)